Is CABA or CELZ more undervalued in 2026?

CirclFi compares Cabaletta Bio, Inc. (CABA) and Creative Medical Technology Hol (CELZ) using 13 institutional-grade valuation models. CABA has a Quality of Company score of 4.4/10 while CELZ scores 5.1/10.

Which is a better buy — CABA or CELZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CABA and CELZ valuations compare?

CABA at $3.78 and CELZ at $2.25 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CABA vs CELZ Valuation Comparison 2026 — Intrinsic Value Analysis

CABA

Biological Products, (No Diagnostic Substances)

Cabaletta Bio, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$3.78

Last close

Models

7/13

Active

CELZ

Biological Products, (No Diagnostic Substances)

Creative Medical Technology Hol

Quality

5.1

out of 10

Value Trap

WARN

Price

$2.25

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	CABA Fair Value	CABA Upside	CELZ Fair Value	CELZ Upside
Bayesian DCF	Intrinsic	$1.06	-72.1%	$1.46	-34.9%
Earnings Power Value	Intrinsic	—	—	$1.63	-27.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.45	-61.5%	$1.54	-31.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CABA vs CELZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CABA vs CELZ — Which Stock Is More Undervalued?

CELZ scores higher with a 5.1/10 quality rating vs CABA's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cabaletta Bio, Inc. (CABA) and Creative Medical Technology Hol (CELZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CABA currently trades at $3.78 with a QOC of 4.4/10, while CELZ trades at $2.25 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).